Jaime is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an assistant editor.
She has a BA in print journalism from Penn State University. You can connect with Jaime on LinkedIn.
Success in Eosinophil-Targeted Treatments for EoE Remains Limited
September 2nd 2022The researchers compiled data from studies of lirentelimab, mepolizumab, reslizumab, and benralizumab, highlighting the difficulties in finding an effective approach with eosinophil-targeted treatments for eosinophilic esophagitis (EoE).
Read More
DIY Automated Insulin Delivery Systems Bring Unique Challenges to HCPs
August 27th 2022Do-it-yourself (DIY) automated insulin delivery systems have gained rapid uptake, yielding self-reported improvements in glycemic control and quality of life for patients, but creating unique challenges for health care providers (HCPs).
Read More
Nusinersen Linked With Modest Improvements in Adult SMA
August 26th 2022The patients, from 5 referral centers, were followed for at least 6 months and showed modest improvements in both motor and functional scales when treated with the antisense oligonucleotide for spinal muscular atrophy (SMA).
Read More
Researchers Offer Guidance on Choosing Appropriate BTK Inhibitor in CLL
August 25th 2022Offering an effective, tolerable, and chemotherapy-free option for patients with chronic lymphocytic leukemia (CLL), Bruton’s tyrosine kinase (BTK) inhibitors have drastically changed the disease’s landscape.
Read More
COPD Transition Bundle May Lower Risk of Hospital Readmission
August 24th 2022Findings from this multicenter randomized controlled trial showed that the transition bundle was associated with a lower risk of 7-day and 30-day hospital readmission from chronic obstructive pulmonary disease (COPD).
Read More
CAR T-Cell Therapy Outcomes Likely Not Influenced by Race/Ethnicity, Obesity
August 21st 2022Researchers studied data from 5 phase 1 studies that took place between 2012 and 2021, comprising 139 infusions among patients with B-cell acute lymphoblastic leukemia who received chimeric antigen receptor (CAR) T-cell treatment.
Read More
Real-world Data Confirm Early Efficacy of Anti-IL-17A Inhibitors for Psoriasis
August 17th 2022Treatment with anti-interleukin (IL)-17A inhibitors for psoriasis consistently improved outcomes across primary and secondary endpoints compared with all other approved biologics, and researchers also found differences between anti-IL-17A inhibitors.
Read More
TNF Inhibitors Linked to Higher Risk of Psoriasis in Patients With IBD, RA
August 16th 2022While noting that providers and their patients should be aware of the potential risk, the researchers underscored that the risk of new-onset psoriasis due to tumor necrosis factor-α inhibitor (TNFi) treatment appears to be rare and that strategies do not need to change for patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) and/or rheumatoid arthritis (RA).
Read More
Parents of Youth With T1D Generally Prefer Virtual Visit for CGM Initiation
August 15th 2022The interview-based study collected feedback from 16 parents of 15 youth recently diagnosed with type 1 diabetes, finding that the majority preferred a virtual continuous glucose monitoring (CGM) information initiation visit rather than an in-person visit.
Read More
CAR T Outcomes Not Significantly Affected by rrDLBCL Subgroup
August 9th 2022With 40% of patients with diffuse large B-cell lymphoma experiencing relapsed or refractory disease (rrDLBCL), researchers highlighted the promise of chimeric antigen receptor (CAR) T-cell therapy for these patients.
Read More
Three CAR T-Cell Trials, 2 Outcomes, for Second-line LBCL Therapy
August 4th 2022Both the ZUMA-7 trial for axicabtagene ciloleucel—approved for second-line treatment earlier this year—and the TRANSFORM trial for lisocabtagene maraleucel showed significant improvement over standard of care for large B cell lymphoma (LBCL), while the BELINDA trial for tisagenlecleucel did not.
Read More
Phase 3 Study: Zanubrutinib Improves PFS Over Chemoimmunotherapy in Untreated CLL, SLL
August 4th 2022The findings, coming from the phase 3 SEQUOIA study, found that the next-generation, selective Bruton tyrosine kinase inhibitor had superior efficacy versus chemoimmunotherapy and demonstrated an acceptable safety profile among 600 older patients with comorbidities.
Read More
For Early-Stage cHL Survivors, CVD Has Surpassed Neoplasms as Leading Cause of Death
August 3rd 2022Cardiovascular disease (CVD) has, over time, becoming the leading cause of death for patients with early-stage classic Hodgkin lymphoma (cHL), surpassing the risk of death from cHL and other cancers.
Read More
New Findings May Have Implications for PH Classification
July 8th 2022Researchers have found that patients who have idiopathic pulmonary arterial hypertension (IPAH) with a phenotype characterized by a smoking history and low diffusion capacity for carbon monoxide had little in common with patients with classical IPAH.
Read More